• Kronos Alliance Manager for Genentech research collaboration
• Lead key US market access initiatives including development of pricing, reimbursement and contracting strategy and related implementation, development of a compelling economic value proposition and core value dossier development, and reimbursement strategy until phase 3 program terminated in Nov 2022
• From Nov'22 – Nov'23: VP, Commercial Strategy and Alliance Management

Launched Pepaxto, an infused peptide-drug-conjugate indicated for Relapsed/refractory Multiple Myeloma
• Built Market Access team and remit for Pepaxto: designed and built supply chain, distribution, payer, patient support, and pricing and contracting models for Pepaxto de novo; currently leading a team of 12 professionals spanning in-house roles (pricing and contracting, reimbursement/patient assistance, trade/supply chain and GPO contracting), and customer-facing roles (National Account Managers focused on payers, GPOs, patients, providers), while successfully adhering to a $4.1M annual outside spend budget
• Demonstrated clear launch successes: ensured that labelled drug was in channel within 14 days of FDA approval; successful pre- and post-payer engagement leading to 100% of covered lives under published non Medicare FFS payer policies aligned to the label (68%+ of US lives); fully functional patient and reimbursement support call center live at launch; recommended and secured l

Executive Director (Jul'19); Sr. Director (Sep'17), Director (Sep'15): Launched HEPLISAV-B, an adjuvanted two dose 30 day adult HepB vaccine with Nov'17 FDA approval date; commercial pipeline support of two clinical-stage immuno oncology assets
● • Significant contributor to ~30% QoQ growth rate since Nov'17 HEPLISAV-B launch, via personal direct top-30 customer engagement, market-based end-user contracting initiatives, and distribution and payer market access initiatives.
• Account Management and contract negotiations: Personally presented to or coached sales leaders for top-tier customer engagement on topics such as: Health Economics, Net Cost Recovery, pricing concerns, or navigating competitor contracts. Directly led procurement contracting negotiations across top IDNs (Kaiser, Inter-mountain, UPMC, etc.), retail partners (Walgreens, Walmart, etc.), and other large accounts (Fresenius, DaVita, e.g.) across all Classes of Trade; direct responsibility for Kaiser as a personal accou

Launch planning for Gevokizumab (Ph3 product for orphan disease Behcet's Disease Uveitis, missed primary endpoint)
• Go-to-market strategy development: active member of the commercial leadership team, contributor to cross functional planning (Pricing Committee, Revenue Recognition, etc.), developed 3 year market access plan
• Distribution planning: Designed high-touch channel strategy for ultra-orphan product spanning both medical and pharmacy benefit types; solved for multiple site of care options: buy-and-bill, specialty pharmacy, or home nurse injection. Secured leadership, CEO, and board approval. Identified channel partners, advanced MSAs and SOWs.
• Payer strategy: Assessed payer mix and national and regional payer policies towards orphan biologics, segmented payers based on likely utilization management levers, assessed price and PMPM impact, developed mock payer policy and Prior Authorization criteria, conducted payer research, and created Value Proposition, plans for contra

Managed Care Marketing for Xtandi(oral androgen receptor indicated for Castration-Resistant Prostate Cancer) via
co-promotion agreement with Astellas Pharma US Inc.
• Navigated co-promote environment: Effective influencer of jointly-led market access initiatives, balancing Medivation objectives alongside Astellas Market Access priorities.
• Managed care strategy and tactics: Optimized access to Xtandi through a variety of market access channels: trade, payer, pathway, practice management; implement though work with cross-functional groups and Medivation's co-promote partner
• Pilot development: Selectively developed regional payer/ACO pilot initiatives aimed at implementing novel access strategies
• Field support: Worked with National Account Managers and sales team leadership to understand customer and industry trends/opportunities & developed tools and programs to address them
• Payer evidence planning: developed cross-functional forum & worked with HEOR and publication plannin

• Oncology-specific focus: Managed Care Marketing support for Account Managers with key accounts: USON, ION, VitalSource; supporting MCCO-driven initiatives such as wholesaler to Specialty Distributor conversion
• Team leadership: led team of two in pulling-through brand strategies/brand plans to individual trade account plans: full-line, Specialty Distributor, Retail classes of trade and GPOs
• Conference and account planning: developed C-suite executive exchanges between GNE major managed care partners; elevated Genentech exposure at major conferences; support contract negotiations with tools & programs
• Initiatives aimed at buy-and-bill practices: partnered with oncology GPOs to address site of care shift from community oncology setting to hospitals/ACO settings; led multi-stakeholder communication plan for novel community practice discount program
• Specialty Pharmacy (SP) engagement: developed tools to evaluate SP performance
● Market Analysis & Strategy: Group Manager, (Jan

Intramuscular Interferon agent
• Clinical Data Management: Shaped Clinical Protocol development by defining data and analysis requirements; developed tools and processes to collect, validate, and prepare clinical data for statistical analysis; worked with clinical development to manage laboratory data, Case Report Form data, and self-reported outcome measures
• Clinical Study Report (CSR) development: Support Medical Monitor in creating CSR; analyzed and reported data for efficacy and safety

• Clinical development: Clinical data management lead for all early-stage Hepatitis clinical research